Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SQZ-eAPC-HPV,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,375.0 million
Deal Type : Collaboration
SQZ Biotechnologies Provides Update on Collaboration with Roche
Details : Under the collaboration, SQZ Biotechnologies will regain full clinical development and future commercialization rights for its programs including, SQZ-eAPC-HPV, based on antigen presenting cells (APCs) created by the SQZ platform and targeting HPV 16 pos...
Product Name : SQZ-eAPC-HPV
Product Type : Cell and Gene therapy
Upfront Cash : $125.0 million
July 25, 2023
Lead Product(s) : SQZ-eAPC-HPV,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,375.0 million
Deal Type : Collaboration
Lead Product(s) : SQZ-AAC-HPV,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SQZ-AAC-HPV are derived from RBCs engineered with the Cell Squeeze® technology, designed to take advantage of the natural physiological process of aged RBC clearance by resident APCs in lymphoid organs which primes endogenous T cells to potentially driv...
Product Name : SQZ-AAC-HPV
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 22, 2023
Lead Product(s) : SQZ-AAC-HPV,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SQZ-PBMC-HPV,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SQZ-APC-HPV (SQZ-PBMC-HPV) is company’s APC autologous cell therapy clinical candidate and is derived from peripheral blood mononuclear cells, primarily composed of monocytes, T cells, B cells, and NK cells, and engineered tumor specic E6 and E7 peptid...
Product Name : SQZ-PBMC-HPV
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 07, 2022
Lead Product(s) : SQZ-PBMC-HPV,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SQZ-eAPC-HPV,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SQZ-eAPC-HPV are derived from PBMCs, which are primarily composed of monocytes, T cells, B cells, and NK cells, and engineered with various mRNA encoding for multiple target antigens and immuno-stimulatory signals, including CD86 and membrane-bound IL-2 ...
Product Name : SQZ-eAPC-HPV
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 30, 2022
Lead Product(s) : SQZ-eAPC-HPV,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SQZ-AAC-HPV,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SQZ Enhanced Antigen Presenting Cells, derived from peripheral blood mononuclear cells, which are primarily composed of monocytes, T cells, B cells, and NK cells, and engineered with various mRNA encoding for multiple target antigens and immuno-stimulato...
Product Name : SQZ-AAC-HPV
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : SQZ-AAC-HPV,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SQZ-eAPC-HPV,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The SQZ® eAPC platform is the company’s second-generation cell therapy platform which simultaneously delivers five different mRNAs—each encoding for a different protein which plays a part in stimulating key T cell activation signals.
Product Name : SQZ-eAPC-HPV
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 12, 2022
Lead Product(s) : SQZ-eAPC-HPV,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SQZ-PBMC-HPV is an autologous cell therapy candidate comprised of SQZ-engineered antigen presenting cells (APCs) designed to induce CD8 T cell responses against HPV16.
Product Name : SQZ-PBMC-HPV
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 05, 2022
Lead Product(s) : SQZ-PBMC-HPV,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SQZ-PBMC-HPV is being evaluated in a Phase 1/2 clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors. Patients must be positive for the human leukocyte antigen serotype HLA-A*02.
Product Name : SQZ-PBMC-HPV
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : SQZ-PBMC-HPV,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SQZ TACs
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data published, demonstrated that TACs can induce multiple key mechanisms of antigen-specific tolerance in various model systems, including deletion of autoreactive T cells, energy, and expansion of regulatory T cells capable of bystander suppression...
Product Name : SQZ TACs
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : SQZ TACs
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $2.0 million
Deal Type : Funding
Details : With the support of the NIH grant, and building upon our experience in multiplex engineering of immune cells, SQZ researchers will attempt to generate dopaminergic neurons directly from somatic cells.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 21, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $2.0 million
Deal Type : Funding